ehwest, refer to post # 680, an article from clinica.com.uk dated Jan 15,2010
In it is the only data publicly available:
"In studies that have been carried out to date, in up to 1,000 patients, there have been no false-positive results, he said. "There have been several false negatives, but we expect this to be very low once we've refined the test." Although this means there is a slight risk of missing cases of cancer, Dr Schena pointed out that this was better than the current alternative – nothing.
"Arrayit is also working on tests for the early diagnosis of other diseases such as Parkinson's and prostate cancer."
----------------
Also they have said that as result of the specificity they are achieving in their lab work and because their approach is novel to the health care industry, they are committed to communicating proven results rather than discussing speculations. The details of this screening and monitoring test for pre-symptomatic ovarian cancer will be announced after completion of independent trials.
Application for FDA approval is supposed to occur in late 2nd QTR or early 3rd QTR 2010. So, I guess the independent trials must complete before then, at which time they will present the data.
Market Data 
Markets 
AI
